Trial Profile
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium
- 26 May 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2020.
- 26 May 2020 Status changed from recruiting to active, no longer recruiting.